Telix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low - Time to Sell?

Key Points

• Telix Pharmaceuticals shares fell to a new 12-month low of $9.25, after closing at $9.55.
• Despite recent low stock performance, the consensus rating from analysts is a "Moderate Buy" with a target price of $22.33.
• Recent institutional investments include new stakes from several firms, such as ABC Arbitrage SA and Russell Investments Group Ltd..

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $9.25 and last traded at $9.43, with a volume of 282335 shares trading hands. The stock had previously closed at $9.55.

Wall Street Analysts Forecast Growth

TLX has been the topic of several analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $22.00 price objective on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a research report on Wednesday, July 9th. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. Finally, HC Wainwright initiated coverage on Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.33.

Telix Pharmaceuticals Stock Down 0.2%

The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The firm has a 50 day moving average price of $13.22 and a 200 day moving average price of $15.76.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at about $170,000. ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals in the 1st quarter valued at about $451,000. Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $975,000. Jane Street Group LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $564,000. Finally, IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at about $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.